Literature DB >> 31634718

Combining quantitative susceptibility mapping to the morphometric index in differentiating between progressive supranuclear palsy and Parkinson's disease.

Minako Azuma1, Toshinori Hirai2, Takeshi Nakaura3, Mika Kitajima3, Satoshi Yamashita4, Mamoru Hashimoto5, Kazumichi Yamada6, Hiroyuki Uetani3, Yasuyuki Yamashita3, Yi Wang7.   

Abstract

PURPOSE: To determine whether the susceptibility value in the deep gray matter obtained by quantitative susceptibility mapping (QSM) provides additive value to the morphometric index for differentiating progressive supranuclear palsy (PSP) from Parkinson's disease (PD).
MATERIALS AND METHODS: PSP- (n = 8) and PD patients (n = 18) and 18 age-matched healthy controls who underwent QSM and 3D magnetization-prepared rapid gradient echo (MPRAGE) sequences. The mean susceptibility values (MSVs) of the deep gray matter structures on QSM- and areas of the midbrain (morphometric index, MI) on 3D MPRAGE images were measured by two neuroradiologists. Analysis of variance, the Scheffe test and receiver operating characteristic (ROC) analysis were conducted to assess differences and discriminate among PSP, PD and controls by the MSVs and the MI. Using the MSV of a structure with the best area under the curve (AUC) and the MI, we created a decision tree to differentiate between PSP and PD.
RESULTS: The MSVs of the globus pallidus (GP) and substantia nigra (SN) were significantly higher in PSP than PD and the controls (p < .05). By ROC analysis (PSP vs PD), AUC was greatest (0.903) for the GP. The MI was significantly smaller in PSP than PD and the controls (p < .05); AUC (PSP vs PD) was 0.917. The decision tree using cutoff values of 244 parts per billion for MSV of the GP and 74.0 mm2 for MI served to completely differentiate between PSP and PD.
CONCLUSION: The MSV in the GP on QSM images adds value to the MI for differentiating PSP from PD.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  MRI; Parkinson's disease; Progressive supranuclear palsy; Quantitative susceptibility mapping

Year:  2019        PMID: 31634718     DOI: 10.1016/j.jns.2019.116443

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  6 in total

Review 1.  Brain Glucose Hypometabolism and Iron Accumulation in Different Brain Regions in Alzheimer's and Parkinson's Diseases.

Authors:  Indira Y Rao; Leah R Hanson; Julia C Johnson; Michael H Rosenbloom; William H Frey
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-29

2.  Application of Quantitative Magnetic Resonance Imaging in the Diagnosis of Autism in Children.

Authors:  Shilong Tang; Lisha Nie; Xianfan Liu; Zhuo Chen; Yu Zhou; Zhengxia Pan; Ling He
Journal:  Front Med (Lausanne)       Date:  2022-05-12

3.  Quantitative susceptibility mapping and blood neurofilament light chain differentiate between parkinsonian disorders.

Authors:  Piao Zhang; Junling Chen; Tongtong Cai; Chentao He; Yan Li; Xiaohong Li; Zhenzhen Chen; Lijuan Wang; Yuhu Zhang
Journal:  Front Aging Neurosci       Date:  2022-08-05       Impact factor: 5.702

4.  Morphometric imaging and quantitative susceptibility mapping as complementary tools in the diagnosis of parkinsonisms.

Authors:  Sonia Mazzucchi; Eleonora Del Prete; Mauro Costagli; Daniela Frosini; Davide Paoli; Gianmichele Migaleddu; Paolo Cecchi; Graziella Donatelli; Riccardo Morganti; Gabriele Siciliano; Mirco Cosottini; Roberto Ceravolo
Journal:  Eur J Neurol       Date:  2022-06-27       Impact factor: 6.288

Review 5.  [MRI Findings in Parkinson's Disease: Radiologic Assessment of Nigrostriatal Degeneration].

Authors:  Yun Jung Bae; Jong-Min Kim; Byung Se Choi; Yoo Sung Song; Yoonho Nam; Se Jin Cho; Jae Hyoung Kim; Sang Eun Kim
Journal:  Taehan Yongsang Uihakhoe Chi       Date:  2022-05-25

6.  Diagnostic Performance of the Magnetic Resonance Parkinsonism Index in Differentiating Progressive Supranuclear Palsy from Parkinson's Disease: An Updated Systematic Review and Meta-Analysis.

Authors:  Seongken Kim; Chong Hyun Suh; Woo Hyun Shim; Sang Joon Kim
Journal:  Diagnostics (Basel)       Date:  2021-12-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.